Drug Index


Mechanism :

Defibrotide augments plasmin enzymatic activity to hydrolyse fibrin clots. t reduces endothelial cell (EC) activation and increases EC-mediated fibrinolysis by increasing tissue plasminogen activator and thrombomodulin expression, as well as by decreasing von Willebrand factor and plasminogen activator inhibitor-1 expression.

Indication :

  • Hepatic sinusoidal obstruction syndrome

Contraindications :

Known hypersensitivity to defibrotide or any component of the formulation; concomitant administration with systemic anticoagulant or fibrinolytic therapy.

Dosing :

>1 month:
6.25 mg/kg every 6 hours for at least 21 days and up to a maximum of 60 days.

Adverse Effect :

Hypotension, diarrhea, vomiting, nausea, haemorrhage, epistaxis, hyperuricemia, hypersensitivity reactions, graft versus host disease, sepsis.

Interaction :

Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant and anti-platelet effect of Thrombolytic Agents.
Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.

Hepatic Dose :

No dosage adjustments are recommended.
01/23/2024 12:14:07 Defbrotide
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0